Emisphere's Eligen GLP-1 and PYY3-36 cuts appetite

US drug delivery specialist Emisphere Technologies has reported strong appetite suppression data with oral administration of two peptides,  GLP-1 and PYY3-36, utilizing its Eligen Technology.

The randomized, double-blind, placebo-controlled trial, conducted in 16  normal weight males between the ages of 18 and 40, found that these  orally-administered peptides, when delivered with Emisphere's SNAC  carrier system, were rapidly absorbed from the gastrointestinal tract,  leading to concentrations several times higher than endogenous hormone  levels achieved after a standard test meal. Specifically, results showed  that oral GLP-1 (2mg tablet) alone and the combination of oral GLP-1  (2mg tablet) plus PYY3-36 (1mg tablet) induced a significant reduction  in calorie intake although there was no synergistic effect when the two  peptides were used in combination.

Oral PYY3-36 at a 1mg dose by itself did not significantly reduce  calorie intake. Oral GLP-1 (2mg tablet) and oral PYY3-36 (1mg tablet)  were both shown to induce a rapid increase in plasma GLP-1 and plasma  PYY concentrations, respectively.